Teriparatide Treatment for Hypercalcemia Associated With Adynamic Bone Disease

Overview

Journal JBMR Plus

Publisher Oxford University Press

Date 2019 Aug 3

PMID 31372586

Citations 5

Authors

Jennifer Peugh

Andrew Khalil

Micah R Chan

Karen E Hansen

Affiliations

Soon will be listed here.

Abstract

Hypercalcemia most often results from primary hyperparathyroidism and malignancy. Adynamic bone disease (ABD) is a form of renal osteodystrophy characterized by reduced bone turnover, which can limit the ability of bone to release or store calcium, potentially leading to low, normal, or high serum calcium levels. We describe a 51-year-old dialysis-dependent female with hypercalcemia after parathyroidectomy. A demeclocycline-labeled bone biopsy confirmed adynamic bone disease. Teriparatide, a recombinant form of parathyroid hormone (PTH) used to treat postmenopausal osteoporosis, was prescribed for 12 months and normalized serum calcium levels. Although previous case reports and series have described favorable changes in spine bone mineral density when teriparatide was prescribed for ABD, ours is the first documented case in which teriparatide resolved hypercalcemia due to ABD. © 2019 The Authors. published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

Citing Articles

Renal replacement therapy in sarcoidosis.

Calatroni M, Moroni G, Ponticelli C Front Med (Lausanne). 2023; 9:990252.

PMID: 36698835 PMC: 9870065. DOI: 10.3389/fmed.2022.990252.

Vitamin D and the Kidney: Two Players, One Console.

Zappulo F, Cappuccilli M, Cingolani A, Scrivo A, Chiocchini A, Nunzio M Int J Mol Sci. 2022; 23(16).

PMID: 36012412 PMC: 9409427. DOI: 10.3390/ijms23169135.

Adynamic bone disease.

Gueiros A, de Oliveira R, Carvalho A J Bras Nefrol. 2021; 43(4 Suppl 1):650-653.

PMID: 34910800 PMC: 8823915. DOI: 10.1590/2175-8239-JBN-2021-S108.

Treatment of Severe Tumoral Calcinosis with Teriparatide in a Dialysis Patient after Total Parathyroidectomy.

Sin H, Wong P, Lo K, Lo M, Chan S, Lo K Case Rep Nephrol. 2021; 2021:6695906.

PMID: 33505741 PMC: 7808806. DOI: 10.1155/2021/6695906.

Immune Modulator Protein rLZ-8 Could Prevent and Reverse Bone Loss in Glucocorticoids-Induced Osteoporosis Rat Model.

Yang Y, Yu T, Tang H, Ren Z, Li Q, Jia J Front Pharmacol. 2020; 11:731.

PMID: 32508652 PMC: 7248554. DOI: 10.3389/fphar.2020.00731.

References

Cejka D, Kodras K, Bader T, Haas M . Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study. Kidney Blood Press Res. 2010; 33(3):221-6. DOI: 10.1159/000316708. View

Sista S, Arum S . Management of adynamic bone disease in chronic kidney disease: A brief review. J Clin Transl Endocrinol. 2017; 5:32-35. PMC: 5644430. DOI: 10.1016/j.jcte.2016.07.002. View

Frazao J, Martins P . Adynamic bone disease: clinical and therapeutic implications. Curr Opin Nephrol Hypertens. 2009; 18(4):303-7. DOI: 10.1097/MNH.0b013e32832c4df0. View

Fahrleitner-Pammer A, Wagner D, Krisper P, Amrein K, Dimai H . Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report. Osteoporos Int. 2016; 28(3):1149-1152. PMC: 5406430. DOI: 10.1007/s00198-016-3858-2. View

Malluche H, Mawad H, Monier-Faugere M . Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res. 2011; 26(6):1368-76. PMC: 3312761. DOI: 10.1002/jbmr.309. View

Sprague S, Bellorin-Font E, Jorgetti V, Carvalho A, Malluche H, Ferreira A . Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis. 2015; 67(4):559-66. DOI: 10.1053/j.ajkd.2015.06.023. View

Yee-Moon Wang A . Calcium balance and negative impact of calcium load in peritoneal dialysis patients. Perit Dial Int. 2014; 34(4):345-52. PMC: 4079479. DOI: 10.3747/pdi.2013.00177. View

Mitsopoulos E, Ginikopoulou E, Economidou D, Zanos S, Pateinakis P, Minasidis E . Impact of long-term cinacalcet, ibandronate or teriparatide therapy on bone mineral density of hemodialysis patients: a pilot study. Am J Nephrol. 2012; 36(3):238-44. DOI: 10.1159/000341864. View

LAFFERTY F . Differential diagnosis of hypercalcemia. J Bone Miner Res. 1991; 6 Suppl 2:S51-9; discussion S61. DOI: 10.1002/jbmr.5650061413. View

10.

. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113):S1-130. DOI: 10.1038/ki.2009.188. View

11.

Giamalis P, Economidou D, Dimitriadis C, Memmos D, Papagianni A, Efstratiadis G . Treatment of adynamic bone disease in a haemodialysis patient with teriparatide. Clin Kidney J. 2015; 8(2):188-90. PMC: 4370305. DOI: 10.1093/ckj/sfv005. View

12.

Lehmann G, Ott U, Maiwald J, Wolf G . Bone histomorphometry after treatment with teriparatide (PTH 1-34) in a patient with adynamic bone disease subsequent to parathyroidectomy. NDT Plus. 2015; 2(1):49-51. PMC: 4421499. DOI: 10.1093/ndtplus/sfn169. View

13.

Palcu P, Dion N, Ste-Marie L, Goltzman D, Radziunas I, Miller P . Teriparatide and bone turnover and formation in a hemodialysis patient with low-turnover bone disease: a case report. Am J Kidney Dis. 2015; 65(6):933-6. DOI: 10.1053/j.ajkd.2015.01.025. View

14.

Miller P, Schwartz E, Chen P, Misurski D, Krege J . Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int. 2006; 18(1):59-68. DOI: 10.1007/s00198-006-0189-8. View

15.

Bover J, Urena P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I . Adynamic bone disease: from bone to vessels in chronic kidney disease. Semin Nephrol. 2014; 34(6):626-40. DOI: 10.1016/j.semnephrol.2014.09.008. View

16.

. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl (2011). 2019; 7(1):1-59. PMC: 6340919. DOI: 10.1016/j.kisu.2017.04.001. View

17.

Kanis J, Adachi J, Cooper C, Clark P, Cummings S, Diaz-Curiel M . Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. Osteoporos Int. 2013; 24(11):2763-4. PMC: 5096926. DOI: 10.1007/s00198-013-2413-7. View

18.

Waghray A, Milas M, Nyalakonda K, Siperstein A . Falsely low parathyroid hormone secondary to biotin interference: a case series. Endocr Pract. 2013; 19(3):451-5. DOI: 10.4158/EP12158.OR. View

19.

Bushinsky D . Contribution of intestine, bone, kidney, and dialysis to extracellular fluid calcium content. Clin J Am Soc Nephrol. 2010; 5 Suppl 1:S12-22. DOI: 10.2215/CJN.05970809. View

20.

Klemmer P . Calcium loading, calcium accumulation, and associated cardiovascular risks in dialysis patients. Blood Purif. 2005; 23 Suppl 1:12-9. DOI: 10.1159/000083713. View